Tomas Vaisar1, Jenny E Kanter1, Jake Wimberger1, Angela D Irwin1, John Gauthier2, Emily Wolfson2, Vanessa Bahnam2, I-Hsien Wu2, Hetal Shah2,3, Hillary A Keenan2, Carla J Greenbaum4, George L King2,3, Jay W Heinecke1, Karin E Bornfeldt5,6. 1. Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington School of Medicine, Seattle, WA. 2. Research Division, Joslin Diabetes Center, Boston, MA. 3. Department of Medicine, Harvard Medical School, Boston, MA. 4. Diabetes Program, Benaroya Research Institute, Seattle, WA. 5. Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington Medicine Diabetes Institute, University of Washington School of Medicine, Seattle, WA bornf@uw.edu. 6. Department of Pathology, University of Washington Medicine Diabetes Institute, University of Washington School of Medicine, Seattle, WA.
Abstract
OBJECTIVE: A subset of people with long-standing type 1 diabetes (T1D) appears to be protected from microvascular and macrovascular complications. Previous studies have focused on improved abilities to respond to glucose and its downstream effects as protective mechanisms. It is unclear whether lipoproteins play a role in the vascular health of these people. We therefore determined whether HDL particle concentration, size, function, and/or protein composition associate with protection from vascular complications. RESEARCH DESIGN AND METHODS: We studied two independent cross-sectional cohorts with T1D: the T1D Exchange Living Biobank (n = 47) and the Joslin Medalist Study (n = 100). Some of the subjects had vascular complications, whereas others never exhibited vascular complications, despite an average duration of diabetes in the cohorts of 45 years. We assessed HDL particle size and concentration by calibrated ion mobility analysis, the HDL proteome by targeted mass spectrometry, and HDL function ex vivo by quantifying cholesterol efflux capacity and inhibition of monocyte adhesion to endothelial cells. RESULTS: In both cohorts, people without vascular complications exhibited significantly higher concentrations of medium-sized HDL particles (M-HDL) independently of total and HDL cholesterol levels. While no consistent differences in HDL functions were observed ex vivo, people without vascular complications had higher levels of HDL-associated paraoxonase 1 (PON1), an enzyme that inhibits atherosclerosis in animal models. CONCLUSIONS: Elevated concentrations of M-HDL particles and elevated levels of HDL-associated PON1 may contribute to long-term protection from the vascular complications of diabetes by pathways that are independent of total cholesterol and HDL cholesterol.
OBJECTIVE: A subset of people with long-standing type 1 diabetes (T1D) appears to be protected from microvascular and macrovascular complications. Previous studies have focused on improved abilities to respond to glucose and its downstream effects as protective mechanisms. It is unclear whether lipoproteins play a role in the vascular health of these people. We therefore determined whether HDL particle concentration, size, function, and/or protein composition associate with protection from vascular complications. RESEARCH DESIGN AND METHODS: We studied two independent cross-sectional cohorts with T1D: the T1D Exchange Living Biobank (n = 47) and the Joslin Medalist Study (n = 100). Some of the subjects had vascular complications, whereas others never exhibited vascular complications, despite an average duration of diabetes in the cohorts of 45 years. We assessed HDL particle size and concentration by calibrated ion mobility analysis, the HDL proteome by targeted mass spectrometry, and HDL function ex vivo by quantifying cholesterol efflux capacity and inhibition of monocyte adhesion to endothelial cells. RESULTS: In both cohorts, people without vascular complications exhibited significantly higher concentrations of medium-sized HDL particles (M-HDL) independently of total and HDL cholesterol levels. While no consistent differences in HDL functions were observed ex vivo, people without vascular complications had higher levels of HDL-associated paraoxonase 1 (PON1), an enzyme that inhibits atherosclerosis in animal models. CONCLUSIONS: Elevated concentrations of M-HDL particles and elevated levels of HDL-associated PON1 may contribute to long-term protection from the vascular complications of diabetes by pathways that are independent of total cholesterol and HDL cholesterol.
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: Brendan MacLean; Daniela M Tomazela; Nicholas Shulman; Matthew Chambers; Gregory L Finney; Barbara Frewen; Randall Kern; David L Tabb; Daniel C Liebler; Michael J MacCoss Journal: Bioinformatics Date: 2010-02-09 Impact factor: 6.937
Authors: Christian Besler; Kathrin Heinrich; Lucia Rohrer; Carola Doerries; Meliana Riwanto; Diana M Shih; Angeliki Chroni; Keiko Yonekawa; Sokrates Stein; Nicola Schaefer; Maja Mueller; Alexander Akhmedov; Georgios Daniil; Costantina Manes; Christian Templin; Christophe Wyss; Willibald Maier; Felix C Tanner; Christian M Matter; Roberto Corti; Clement Furlong; Aldons J Lusis; Arnold von Eckardstein; Alan M Fogelman; Thomas F Lüscher; Ulf Landmesser Journal: J Clin Invest Date: 2011-06-23 Impact factor: 14.808
Authors: Amit V Khera; Olga V Demler; Steven J Adelman; Heidi L Collins; Robert J Glynn; Paul M Ridker; Daniel J Rader; Samia Mora Journal: Circulation Date: 2017-04-27 Impact factor: 29.690
Authors: John M Lachin; Neil H White; Dean P Hainsworth; Wanjie Sun; Patricia A Cleary; David M Nathan Journal: Diabetes Date: 2014-09-09 Impact factor: 9.461
Authors: Tatjana Josefs; Debapriya Basu; Tomas Vaisar; Britt Arets; Jenny E Kanter; Lesley-Ann Huggins; Yunying Hu; Jianhua Liu; Noemie Clouet-Foraison; Jay W Heinecke; Karin E Bornfeldt; Ira J Goldberg; Edward A Fisher Journal: Circ Res Date: 2021-02-03 Impact factor: 17.367
Authors: Vasily A Kudinov; Olga Yu Alekseeva; Tatiana I Torkhovskaya; Konstantin K Baskaev; Rafael I Artyushev; Irina N Saburina; Sergey S Markin Journal: Int J Mol Sci Date: 2020-11-19 Impact factor: 5.923
Authors: Philip W Connelly; Andrew T Yan; Michelle M Nash; Rachel M Wald; Charmaine Lok; Lakshman Gunaratnam; Anish Kirpalani; G V Ramesh Prasad Journal: Front Cardiovasc Med Date: 2021-12-02
Authors: Jaume Amengual; Yoscar Ogando; Cyrus Nikain; Alexandra Quezada; Kun Qian; Tomas Vaisar; Edward A Fisher Journal: Mol Pharmacol Date: 2020-12-31 Impact factor: 4.436